Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Purpose: No established treatment exists for pancreatic neuroendocrine tumor (NET) progression after failure of chemotherapy. Everolimus (RAD001), an oral inhibitor of mammalian target of rapamycin, in combination with octreotide has demonstrated encouraging antitumor activity in patients with NETs. Patients and Methods: This open-label, phase II study assessed the clinical activity of everolimus in patients with metastatic pancreatic NETs who experienced progression on or after chemotherapy. Patients were stratified by prior octreotide therapy (stratum 1: everolimus 10 mg/d, n = 115; stratum 2: everolimus 10 mg/d plus octreotide long-acting release [LAR], n = 45). Tumor assessments (using Response Evaluation Criteria in Solid Tumors) were performed every 3 months. Chromogranin A (CgA) and neuron-specific enolase (NSE) were assessed monthly if elevated at baseline. Trough concentrations of everolimus and octreotide were assessed. Results: By central radiology review, in stratum 1, there were 11 partial responses (9.6%), 78 patients (67.8%) with stable disease (SD), and 16 patients (13.9%) with progressive disease; median progression-free survival (PFS) was 9.7 months. In stratum 2, there were two partial responses (4.4%), 36 patients (80%) with SD, and no patients with progressive disease; median PFS was 16.7 months. Patients with an early CgA or NSE response had a longer PFS compared with patients without an early response. Coadministration of octreotide LAR and everolimus did not impact exposure to either drug. Most adverse events were mild to moderate and were consistent with those previously seen with everolimus. Conclusion: Daily everolimus, with or without concomitant octreotide LAR, demonstrates antitumor activity as measured by objective response rate and PFS and is well tolerated in patients with advanced pancreatic NETs after failure of prior systemic chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Yao, J. C., Hassan, M., Phan, A., Dagohoy, C., Leary, C., Mares, J. E., Abdalla, E. K., Fleming, J. B., Vauthey, J.-N., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4377 · Cited by 4,510
Self-citationTemsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Self-citationmTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Rinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
Moertel, C. G., Lefkopoulo, M., Lipsitz, S., Hahn, R. G., & Klaassen, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260804 · Cited by 976
Moertel, C. G., Hanley, J. A., & Johnson, L. A. (1980) · New England Journal of Medicine · doi:10.1056/nejm198011203032101 · Cited by 659
Yao, J. C., Phan, A. T., Chang, D. Z., Wolff, R. A., Hess, K., Gupta, S., Jacobs, C., Mares, J. E., Landgraf, A. N., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7858 · Cited by 649
Self-citation
Cited by
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Self-citationSunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Targeting PI3K/Akt/mTOR Signaling in Cancer
Porta, C., Paglino, C., & Mosca, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00064 · Cited by 1,485
Pavel, M., Öberg, K., Falconi, M., Krenning, E. P., Sundin, A., Perren, A., & Berruti, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.304 · Cited by 1,179
Pavel, M. E., Hainsworth, J. D., Baudin, E., Peeters, M., Hörsch, D., Winkler, R. E., Klimovsky, J., Lebwohl, D., Jehl, V., Wolin, E. M., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61742-x · Cited by 1,058
Self-citationTargeting PI3K/mTOR Signaling in Cancer
Arcaro, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00084 · Cited by 1,024
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Pavel, M., Baudin, E., Couvelard, A., Krenning, E., Öberg, K., Steinmüller, T., Anlauf, M., Wiedenmann, B., & Salazar, R. (2012) · Neuroendocrinology · doi:10.1159/000335597 · Cited by 873
Self-citationZaknun, J. J., Bodei, L., Mueller-Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O’Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2330-6 · Cited by 818
Imhof, A., Brunner, P., Marincek, N., Briel, M., Schindler, C., Rasch, H., Mäcke, H. R., Rochlitz, C., Müller-Brand, J., & Walter, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7873 · Cited by 641
Gastroenteropancreatic Neuroendocrine Tumors
Cives, M., & Strosberg, J. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21493 · Cited by 586
Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects
Isgrò, M. A., Bottoni, P., & Scatena, R. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-017-7215-0_9 · Cited by 575
Garcia-Carbonero, R., Capdevila, J., Crespo-Herrero, G., Díaz-Pérez, J. A., Martínez del Prado, M. P., Alonso Orduña, V., Sevilla-García, I., Villabona-Artero, C., Beguiristain-Gómez, A., Llanos-Muñoz, M., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq022 · Cited by 419
Somatostatin receptors: From signaling to clinical practice
Theodoropoulou, M., & Stalla, G. K. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.07.005 · Cited by 410
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018
Shah, M. H., Goldner, W. S., Halfdanarson, T. R., Bergsland, E., Berlin, J. D., Halperin, D., Chan, J., Kulke, M. H., Benson, A. B., Blaszkowsky, L. S., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0056 · Cited by 375
Self-citationStrosberg, J. R., Halfdanarson, T. R., Bellizzi, A. M., Chan, J. A., Dillon, J. S., Heaney, A. P., Kunz, P. L., O’Dorisio, T. M., Salem, R., Segelov, E., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000850 · Cited by 373
Self-citationNeuroendocrine Tumors, Version 1.2015
Kulke, M. H., Shah, M. H., Benson, A. B., Bergsland, E., Berlin, J. D., Blaszkowsky, L. S., Emerson, L., Engstrom, P. F., Fanta, P., Giordano, T., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0011 · Cited by 360
Self-citationTargeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
Markman, B., Dienstmann, R., & Tabernero, J. (2010) · Oncotarget · doi:10.18632/oncotarget.188 · Cited by 355
Kulke, M. H., Siu, L. L., Tepper, J. E., Fisher, G., Jaffe, D., Haller, D. G., Ellis, L. M., Benedetti, J. K., Bergsland, E. K., Hobday, T. J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2056 · Cited by 304
Self-citationA phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
Witzig, T. E., Reeder, C. B., LaPlant, B. R., Gupta, M., Johnston, P. B., Micallef, I. N., Porrata, L. F., Ansell, S. M., Colgan, J. P., Jacobsen, E. D., et al. (2011) · Leukemia · doi:10.1038/leu.2010.226 · Cited by 297
(2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0050 · Cited by 292
Yao, J. C., Pavel, M., Lombard-Bohas, C., Van Cutsem, E., Voi, M., Brandt, U., He, W., Chen, D., Capdevila, J., de Vries, E. G. E., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.0702 · Cited by 274
Self-citationMarotta, V., Zatelli, M. C., Sciammarella, C., Ambrosio, M. R., Bondanelli, M., Colao, A., & Faggiano, A. (2018) · Endocrine-Related Cancer · doi:10.1530/erc-17-0269 · Cited by 161
Knigge, U., Capdevila, J., Bartsch, D. K., Baudin, E., Falkerby, J., Kianmanesh, R., Kos-Kudla, B., Niederle, B., Nieveen van Dijkum, E., O'Toole, D., et al. (2017) · Neuroendocrinology · doi:10.1159/000458155 · Cited by 136
Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy
de Wilde, R. F., Edil, B. H., Hruban, R. H., & Maitra, A. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.9 · Cited by 122
Treatment of Liver Metastases in Patients with Neuroendocrine Tumors: A Comprehensive Review
Harring, T. R., Nguyen, N. T. N., Goss, J. A., & O'Mahony, C. A. (2011) · International Journal of Hepatology · doi:10.4061/2011/154541 · Cited by 69
The treatment of hyperinsulinemic hypoglycaemia in adults: an update
On behalf of NIKE Group, Davi′, M. V., Pia, A., Guarnotta, V., Pizza, G., Colao, A., & Faggiano, A. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0536-3 · Cited by 51
Vezzosi, D., Walter, T., Laplanche, A., Raoul, J. L., Dromain, C., Ruszniewski, P., d'Herbomez, M., Guigay, J., Mitry, E., Cadiot, G., et al. (2011) · The International Journal of Biological Markers · doi:10.5301/jbm.2011.8327 · Cited by 43
Self-citationTherapeutic strategies for patients with neuroendocrine neoplasms: current perspectives
Modica, R., Liccardi, A., Minotta, R., Cannavale, G., Benevento, E., & Colao, A. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2099840 · Cited by 37
Metadata
- Authors
- Yao, J. C., Lombard-Bohas, C., Baudin, E., Kvols, L. K., Rougier, P., Ruszniewski, P., Hoosen, S., St. Peter, J., Haas, T., Lebwohl, D., Van Cutsem, E., Kulke, M. H., Hobday, T. J., O'Dorisio, T. M., Shah, M. H., Cadiot, G., Luppi, G., Posey, J. A., & Wiedenmann, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-01-01
- Volume
- 28
- Issue
- 1
- Pages
- 69-76
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2128267006
- Cited by
- 647
- References
- 34
- FWCI
- 44.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.